1/6
08:55 am
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $57.00 price target on the stock.
Low
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $57.00 price target on the stock.
11/26
05:07 pm
supn
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]
Low
Report
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]
11/26
05:00 pm
supn
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
Low
Report
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
11/13
04:30 pm
supn
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
Medium
Report
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
11/6
06:13 am
supn
Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/5
08:04 am
supn
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/4
09:57 pm
supn
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Medium
Report
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
11/4
08:58 pm
supn
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates [Yahoo! Finance]
Medium
Report
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates [Yahoo! Finance]
11/4
04:05 pm
supn
Supernus Announces Third Quarter 2024 Financial Results
Medium
Report
Supernus Announces Third Quarter 2024 Financial Results
10/31
04:14 pm
supn
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 [Yahoo! Finance]
Low
Report
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 [Yahoo! Finance]
10/31
04:10 pm
supn
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
Low
Report
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
10/21
04:29 pm
supn
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results [Yahoo! Finance]
10/21
04:25 pm
supn
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
Low
Report
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
10/18
03:34 pm
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its "neutral" rating re-affirmed by analysts at Piper Sandler.
Low
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its "neutral" rating re-affirmed by analysts at Piper Sandler.
10/18
03:33 pm
supn
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its "buy" rating re-affirmed by analysts at Cowen Inc.
Low
Report
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) had its "buy" rating re-affirmed by analysts at Cowen Inc.
10/17
04:49 pm
supn
Supernus reports Phase 2a data for SPN-820, stock climbs 6% [Seeking Alpha]
Medium
Report
Supernus reports Phase 2a data for SPN-820, stock climbs 6% [Seeking Alpha]
10/17
04:05 pm
supn
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
Low
Report
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
10/10
05:12 pm
supn
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
Medium
Report
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder